Table 1 Patient demographics, selected laboratory values, clinical history, and immunotherapy drugs included in this study

 Median

53.5

 Range

18–84

 Female

29

 Male

21

  < 3

37

  > =3

13

  < =ULN

36

  > ULN

14

 0–1

48

 2

2

  > =3.5 g/dl

46

  < 3.5 g/dl

4

  < 2

43

  > =2

7

 Median

3

 Range

0–12

 Anthracycline

30

 Ifosfamide

14

 Gemcitabine

22

 Docetaxel

13

 Platinum

8

 anti-CCR4 and anti-PD-L1

4

 anti-PD-1

7

 anti-PD-L1

7

 anti-TIM-3

1

 anti-CTLA-4

5

 anti-CTLA-4 and immunomodulator

7

 anti-CTLA-4 and KIT inhibitor

10

 Dendritic cell vaccine

7

 Interleukin-2

1

 anti-TGF-β

1